Laurence E. Chatel

Geneve, GE 1228, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies.

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies.

Journal: Journal for immunotherapy of cancer

Published: March 06, 2025

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.

Journal: Frontiers in immunology

Published: January 30, 2024

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.

Journal: Journal of hematology & oncology

Published: October 19, 2023

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model.

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model.

Journal: Experimental hematology & oncology

Published: January 21, 2022

Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.

Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.

Journal: European journal of immunology

Published: January 15, 2021

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.

Journal: mAbs

Published: March 20, 2020

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity.

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity.

Journal: Antibodies (Basel, Switzerland)

Published: October 30, 2017

Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.

Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.

Journal: The Journal of allergy and clinical immunology

Published: October 07, 2016

Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.

Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.

Journal: Translational research : the journal of laboratory and clinical medicine

Published: March 18, 2016

Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.

Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: January 21, 2014

GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins.

GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins.

Journal: Nature biotechnology

Published: January 17, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026